An interventional study of PAR and HIIT in Physical Activity and Aging, sponsored by Manuel Castillo Garzón. Completed. Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-12.
Sponsored by Manuel Castillo Garzón · Not applicable, Interventional, and Prevention
FIT-AGING will determine the effect of different exercise modalities on α-Klotho protein (primary outcome) in sedentary healthy adults. FIT-AGING also investigate the physiological consequences of activating Klotho gene (secondary outcomes).
Aims: The plasma Klotho protein concentration (α-Klotho protein), which is considered a powerful biomarker of longevity, makes it an attractive target as an anti-aging therapy against functional decline, sarcopenic obesity, metabolic and cardiovascular diseases, osteoporosis, and neurodegenerative disorders. Physical exercise and physical fitness, could be α-Klotho protein activators through biochemical process. FIT-AGING will determine the effect of different exercise modalities on α-Klotho protein (primary outcome) in sedentary healthy adults. FIT-AGING also investigate the physiological consequences of activating Klotho gene (secondary outcomes).
Methods: FIT-AGING will recruit 60 sedentary, healthy, adults (50% women) aged 40-65 years. Eligible participants will be randomly assigned to a non-exercise group to the usual control group (n=15), physical activity recommendation from American College of Sport Medicine, World Health Organization and American Heart Association group (n=15), High Intensity Interval Training group (n=15)) and Whole-Body Electromyostimulation group (n=15). Laboratory measures completed at baseline and 12 weeks later, include α-Klotho protein concentration, physical fitness (cardiorespiratory fitness, muscular strength), body composition, resting metabolic rate, hearth rate variability (HRV), health blood biomarkers, free-living physical activity, sleep habits reaction time, cognitive variables and health-related questionnaires. The investigators will also obtain dietary habits data and cardiovascular disease risk factors.
Exclusion Criteria:
Non-Exercise group. We will provide general advices to control group participants thought an information meeting performed by a graduate in Sport Sciences. It will recommended to follow the physical activity recommendations for adults provided by World Health Organization
The volume in PAR is based on the minimum physical activity recommended (150min/week at moderate intensity). Intensity selected for PAR aerobic training is 60-65% HRres. Strength intensity selected was 40-50% of 1 RM. Frequency. PAR group will train 3 days/week, the minimum frequency recommended. Exercises programmed for the aerobic exercise are treadmill, cycle-ergometer and elliptical ergometer in aerobic training part and weight bearing and guided pneumatic machines (involved major upper and lower body muscle group) in resistance training. Training load variation. We propose a gradual progression to control the exercise dose Training periodization divided in two phases of 5 weeks each one, starting with a familiarization phase (2 weeks). Training sessions. Sessions start with a dynamic standardized warm up, which include several muscle activation exercises. Aerobic sessions include compensatory exercises. Training session will be ended with a cooling-down protocol
Other: PAR
The volume in HIIT 40-65 min/week at high intensity. Intensity. Two different protocols: HIIT with long intervals (Type A session), which intensity will be \>95% VO2max and HIIT with short intervals (Type B session), \>120% VO2max. Training frequency two times/week. Type of exercise. Type A session are walking in treadmill with personalized slopes. Eight weight-bearing exercises in circuit form, type B session. Training load variation. Gradual progression to control the exercise dose. Training periodization divided in: familiarization phase, phase I, phase II. Training sessions. Type A: 5 minutes in treadmill at 60% VO2max. After warm-up, participants complete sets corresponding to each training session following the corresponding characteristics. Type B: eight weight-bearing exercises (in circuit form) two times/set with an active rest (walking at 60%VO2max) as many times at as defined. Training session will be ended with a cooling-down protocol
Other: HIIT
WB-EMS training program will be the same than HIIT intervention related to volume, intensity, frequency, type of exercise, training load variation, training periodization and training session. However, electrical impulse will be included in order to assess if WB-EMS training will produce an added effect compared to HIIT. Electrical parameters: We will apply a frequency of 15-33 Hz in type A session. And, we will apply a frequency of 35-75 Hz in type B session. Intensity will be 80-100 mA. Impulse Width adjusted in relation to body segment: thigh zone (400μsec), glute zone (350μsec), abdominal zone (300μsec), dorsal zone (250μsec), cervical (200μsec), chest zone (200μsec) and arm zone (200μsec). Duty cycle. We have programmed a duty cycle of 50-67% in type B session, but duty cycle in type A session will be 99%. RPE impulse: the impulse intensity was individually adapted to generate similar values of rate of perceived exertion (RPE) in Borg CR-10 Scale "5" of "9"
Other: WB-EMS
α-Klotho protein
Plasma Klotho concentrations will be measured by ELISA using a soluble α-Klotho ELISA assay kit.
Time frame: Baseline and through study completion, an average of 12 weeks.
Physical fitness: cardiorespiratory fitness
Cardiorespiratory fitness measure through a maximum treadmill test (VO2max.).
Time frame: Baseline and through study completion, an average of 12 weeks.
Physical fitness: muscular strength.
Muscle strength measure through: Isokinetic strength, Handgrip strength and Core resistance stability.
Time frame: Baseline and post-intervention.Baseline and through study completion, an average of 12 weeks.
Body composition.
Measure by DXA.
Time frame: Baseline and through study completion, an average of 12 weeks.
Resting energy expenditure.
Evaluated by indirect calorimetry with gas analyzer breath by breath.
Time frame: Baseline and through study completion, an average of 12 weeks.
Hearth Rate Variability (HRV).
Measure by Polar RS800CX.
Time frame: Baseline and through study completion, an average of 12 weeks.
Biochemical profile.
General biochemical profile in blood samples
Time frame: Baseline and through study completion, an average of 12 weeks.
Physical activity.
The amount of physical activity will be measured by accelerometer.
Time frame: Baseline and through study completion, an average of 12 weeks.
Reaction time.
Measure by Vienna System.
Time frame: Baseline and through study completion, an average of 12 weeks.
Cognitive test.
Auditory memory tests
Time frame: Baseline and through study completion, an average of 12 weeks.
Dietary assessment.
Measure by 24h recall and Food Frecuency Questionnaire.
Time frame: Baseline and post-Baseline and through study completion, an average of 12 weeks..
Anthopometric measures.
Measure by stadiometer and scale.
Time frame: Baseline and post-Baseline and through study completion, an average of 12 weeks..
Sleep quality.
The quality of sleep will be measured by accelerometer.
Time frame: Baseline and post-Baseline and through study completion, an average of 12 weeks..
Hormones profile
Hormones profile measure in blood samples.
Time frame: Baseline and post-Baseline and through study completion, an average of 12 weeks..
No study locations are listed for this record.
Plan to share: No
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.